Drug Approval | July 14, 2022
Shilpa Medicare’s Unit VI, Bengaluru facility has been issued UK MHRA GMP
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
The inspection was triggered by Shilpa's submission of applications for four ANDA's to seek approval to use this site as an alternate testing laboratory
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
Equity raise to finance growth and investments in the biological space
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
